Sign in

    Teresa Vitali

    Director and Equity Research Analyst at Scotiabank

    Teresa Vitali is a Director and Equity Research Analyst at Scotiabank specializing in the coverage of the Utilities sector, with a particular focus on Canadian publicly listed utilities and infrastructure companies. She covers companies such as Fortis Inc., Emera Inc., Hydro One, and Capital Power, providing in-depth financial analysis and investment recommendations widely recognized by institutional investors. Vitali joined Scotiabank in 2016 after earlier experience as an Associate at TD Securities, bringing over a decade of expertise in capital markets and equity research. She holds a Chartered Financial Analyst (CFA) designation and is registered with FINRA, consistently delivering detailed research that supports robust portfolio returns for clients.

    Teresa Vitali's questions to ALNYLAM PHARMACEUTICALS (ALNY) leadership

    Teresa Vitali's questions to ALNYLAM PHARMACEUTICALS (ALNY) leadership • Q1 2025

    Question

    Teresa Vitali, on for Greg Harrison, asked how Alnylam is leveraging its commercial expertise and what specific strategies are being employed to capture patients switching from tafamidis.

    Answer

    Chief Commercial Officer Tolga Tanguler explained that AMVUTTRA's distinct mechanism of action and compelling HELIOS-B data, where nearly half of patients were already on a stabilizer, position it as a clear first-line option. He added that for patients progressing on stabilizers, AMVUTTRA is a very important treatment option, and the company is already seeing uptake in this switch population.

    Ask Fintool Equity Research AI